Chronic myeloid leukemia (CML) is a disorder of blood stem cells in bone marrow, which leads to a rapid production of white blood cells. Of the patients diagnosed with CML, 95% have the Philadelphia (Ph) chromosome, which means that chromosome 22 is smaller than regular (22 q-). Historically, the median survival time for chronic phase CML patients was four to five years, while the accelerated and blast (profusion of immature red blood cells in circulation) phases had a much shorter survival time. Recently, due to the revolutionary new drug imatinib, CML patients diagnosed early have a higher survival rate. Nevertheless, some patients may show resistance to imatinib, and alternative treatments must be considered (Hochhaus and La Rosée 2004).
Kops, R. (2012). Imatinib Resistance in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. The Science Journal of the Lander College of Arts and Sciences, 5 (2). Retrieved from https://touroscholar.touro.edu/cgi/viewcontent.cgi?article=1148&context=sjlcas